A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs B 244 (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Sponsors AOBiome
- 19 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.
- 08 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.